Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis

[1] Carr TF(2018)Eosinophilic and noneosinophilic asthma Am J Respir Crit Care Med 197 22-37

[2] Zeki AA(2018)Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis Lung 196 517-530

[3] Kraft M(2018)Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a pairwise and Bayesian network meta-analysis Int Immunopharmacol 64 223-231

[4] Iftikhar IH(2019)Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison Journal of Allergy and Clinical Immunology 143 190-200.e20-138

[5] Schimmel M(2017)Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials Clin Exp Allergy 47 129-2141

[6] Bender W(2016)Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 388 2128-2458

[7] Swenson C(2017)Oral glucocorticoid-sparing effect of benralizumab in severe asthma N Engl J Med 376 2448-20

[8] Amrol D(2015)A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma Am J Emerg Med 33 14-2496

[9] He LL(2018)Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma N Engl J Med 378 2486-2485

[10] Zhang L(2018)Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma N Engl J Med 378 2475-44

[1] Carr TF(2018)Eosinophilic and noneosinophilic asthma Am J Respir Crit Care Med 197 22-37

[2] Zeki AA(2018)Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis Lung 196 517-530

[3] Kraft M(2018)Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a pairwise and Bayesian network meta-analysis Int Immunopharmacol 64 223-231

[4] Iftikhar IH(2019)Anti–IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison Journal of Allergy and Clinical Immunology 143 190-200.e20-138

[5] Schimmel M(2017)Comparison of anti-interleukin-5 therapies in patients with severe asthma: global and indirect meta-analyses of randomized placebo-controlled trials Clin Exp Allergy 47 129-2141

[6] Bender W(2016)Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 388 2128-2458

[7] Swenson C(2017)Oral glucocorticoid-sparing effect of benralizumab in severe asthma N Engl J Med 376 2448-20

[8] Amrol D(2015)A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma Am J Emerg Med 33 14-2496

[9] He LL(2018)Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma N Engl J Med 378 2486-2485

[10] Zhang L(2018)Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma N Engl J Med 378 2475-44